A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH)

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2019
This article has no abstract
Epistemonikos ID: 36e79b6203731c7a824bbcfd66c87f93db7e9916
First added on: Apr 17, 2025